<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03485196</url>
  </required_header>
  <id_info>
    <org_study_id>AHQU-2017003</org_study_id>
    <nct_id>NCT03485196</nct_id>
  </id_info>
  <brief_title>The Relationship Between Microsatellite Instability and Efficacy of Fluorouracil Based Adjuvant Chemotherapy in Gastric Cancer After Operation</brief_title>
  <official_title>The Relationship Between Microsatellite Instability and Efficacy of Fluorouracil Based Adjuvant Chemotherapy in Gastric Cancer After Operation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Hospital of Qinghai University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>the Second Hospital of Lanzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qinghai People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Affiliated Hospital of Qinghai University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The relationship between Microsatellite instability and efficacy of fluorouracil based
      adjuvant chemotherapy in gastric cancer after operation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To explore the relationship between Microsatellite instability and efficacy of fluorouracil
      based adjuvant chemotherapy in gastric cancer after operation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 8, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>The time from the primary operation to disease recurrence or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>5 years</time_frame>
    <description>the The time from operation to death or the last follow-up.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>MSI-H group</arm_group_label>
    <description>We use the immunohistochemical expression of mismatch repair proteins (MutS protein homolog 2( MSH2),MutS protein homolog 6( MSH6) and PMS2（postmeiotic segregation increased 2 ）) to Determine the MSI status . When two antibodies or more show negative nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite instability high (MSI-H).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSI-L group</arm_group_label>
    <description>We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status. When one antibodies show negative nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite unstable low (MSI-L).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSS group</arm_group_label>
    <description>We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status . when all the four antibodies show positive nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite stable (MSS).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Microsatellite instability</intervention_name>
    <description>The microsatellite instability status are definite to three type:MSI-H, MSI-L,and MSS. The gastric cancer patients who received D2 resection were included in 3 groups：MSI-H group， MSI-L group，and MSS group. All patient must be accept fluorouracil(5-FU) based adjuvant chemotherapy. We will analyze the relationship between MSI status and efficacy of 5-FU based adjuvant chemotherapy by observing the survival period of patients with different MSI status.</description>
    <arm_group_label>MSI-H group</arm_group_label>
    <arm_group_label>MSI-L group</arm_group_label>
    <arm_group_label>MSS group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        gastric cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histopathology or cytopathology proven gastric cancer;

          2. Operable advanced gastric cancer patients: primary lesions can be completely excision,
             no distant metastasis;

          3. Postoperative patients who can tolerate 5-FU based (5-FU，S-1 or Capecitabine) adjuvant
             chemotherapy;

          4. Life expectancy of at least 6 months;

          5. ECOG（Eastern Cooperative Oncology Group ） score 0-1;

          6. Age: 18~80 years old;

          7. Normal hemodynamic indices before the recruitment (including blood cell count and
             liver/kidney function).

               -  For example: WBC（White blood cell count ）&gt;4.0×109/L; NEU（Neutrophils）&gt;1.5×109/L;
                  PLT（Platelet）&gt;100×109/L;

          8. Roughly normal cardiopulmonary function: No coronary heart disease, myocardial
             infarction, pulmonary heart disease, refractory hypertension;

          9. Not concomitant with other uncontrollable benign diseases before the recruitment;

        9. Voluntarily signed the informed consent.

        Exclusion Criteria:

          1. Advanced gastric cancer patients with distant metastasis and inoperable ;

          2. Patients who cannot tolerate 5-FU based adjuvant chemotherapy;

          3. Pregnant or lactating women;

          4. Patients who have no desire to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiuda Zhao, M.D.</last_name>
    <phone>+869716162732</phone>
    <email>jiudazhao@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Hospital Affiliated to Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enxi Li</last_name>
      <phone>15809317472</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qinghai University Affiliated Hospital</name>
      <address>
        <city>Xining</city>
        <state>Qinghai</state>
        <zip>810000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiuda Zhao, M.D.</last_name>
      <phone>+869716162732</phone>
      <email>jiudazhao@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Qinghai Province</name>
      <address>
        <city>Xining</city>
        <state>Qinghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Kan, M.D</last_name>
      <phone>+8613897584590</phone>
      <email>kanying1208@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2018</study_first_submitted>
  <study_first_submitted_qc>March 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2018</study_first_posted>
  <last_update_submitted>March 31, 2018</last_update_submitted>
  <last_update_submitted_qc>March 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Affiliated Hospital of Qinghai University</investigator_affiliation>
    <investigator_full_name>Jiuda Zhao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Microsatellite Instability</keyword>
  <keyword>Fluorouracil</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Operation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Microsatellite Instability</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

